Navigation Links
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Date:9/21/2007

ary, the dose may be either reduced or withheld in the presence of haematological toxicity (see Summary of Product Characteristics [SPC]). For cisplatin dosage adjustment in combination therapy, see the manufacturer's prescribing information.

The elderly: Gemcitabine has been well tolerated by patients over the age of 65 years, and there is no evidence to suggest that dose adjustments are necessary.

Patients with hepatic and renal impairment: Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired renal function. Clinical studies have not provided sufficient information to allow clear dose recommendation for this patient population.

Periodic checks of liver and kidney functions, including transaminases and serum creatinine, should be performed in patients receiving gemcitabine.

Radical radiotherapy: Gemcitabine should not be used concurrently with radical radiotherapy.

Children: Limited Phase I and II trials in children did not provide sufficient data to establish the efficacy and safety of use of gemcitabine in children.

Contra-indications, Warnings, etc

Contra-indications

Known hypersensitivity to gemcitabine.

Warnings

Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity.

Myelosuppression is short-lived and usually does not result in dose reductions and rarely in discontinuation.

There have been very rare cases of haemolytic uraemic syndrome and/or thrombotic thrombocytopenic purpura (signs of micro-angiopathic haemolytic anaemia, such as rapidly falling haemoglobin with concomitant thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen, or LDH). If this occurs, discontinue gemcitabine immediately. Renal failure may not be reversible, even with discontinuation, and dialysis may be required.

Gemcitabine use in patients with concurrent liver metastases or pre- existing h
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer Treatment
2. Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007
3. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Malvern initiates European user group meetings for chemical imaging
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
11. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014  VentiRx Pharmaceuticals, Inc., a clinical ... and commercialization of novel Toll-like receptor 8 ... Food and Drug Administration (FDA) has granted ... motolimod (VTX-2337) when administered in combination with ... of women with ovarian cancer whose disease ...
(Date:9/2/2014)...   Intrexon Corporation (NYSE: XON ... it has entered into an Exclusive Channel Collaboration (ECC) ... (EURONEXT: SAN and NYSE: SNY ) to ... of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi,s ... This collaboration will leverage Intrexon,s proprietary technology suite plus ...
(Date:9/2/2014)... , Sept. 2, 2014   Veracyte, Inc. (Nasdaq: ... Anderson , president and chief executive officer, will present in ... Healthcare Unplugged Conference 2014 on Monday, September 8, 2014 at ... The live audio webcast and subsequent replay may ... Please connect to the website at least 15 minutes prior ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2
... YORK, Sept. 1, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0559262/Global-CRO-Market-Quantitative-Assessment.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development This ... globally, by phase and market type, R&D ...
... This evening, Novo Nordisk awarded sponsorships totaling ... that educate people living with type 2 diabetes on ... risk of long-term diabetes related complications. The sponsorships are ... aims to promote enduring, sustainable change for people living ...
Cached Medicine Technology:Global CRO Market: Quantitative Assessment 2Global CRO Market: Quantitative Assessment 3Novo Nordisk Partners with Minneapolis Community Groups to Support Diabetes Education Programs 2
(Date:9/2/2014)... 02, 2014 West Hollywood cosmetic ... consultations for Invisalign. This special offer includes a free ... to determine their candidacy for the procedure and answer ... patients may also be eligible for the Summer Invisalign ... of the month of August, patients who choose Invisalign ...
(Date:9/2/2014)... MONDAY, Sept. 1, 2014 (HealthDay News) -- The quality ... overall, and dietary disparity between the rich and poor ... provides the most direct evidence to date that the ... U.S. dietary quality are having some payoff, but it ... study author Dong Wang, a doctoral student in the ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- When it comes to excess ... equal, a new study finds. The research found that ... person,s odds for high blood pressure more than overall body ... of high blood pressure. But it wasn,t clear how the ... to researchers at University of Texas Southwestern Medical Center in ...
(Date:9/2/2014)... Dallas, Texas (PRWEB) September 02, 2014 ... , “North America Resectoscopes Market Outlook to 2020? ... Resectoscopes market. The report provides value, in millions ... prices (in US dollars) within market segments –, ... Electrodes (Monopolar (Disposable and Reusable) Electrodes and Bipolar ...
(Date:9/2/2014)... USARAD Holdings Inc. a leading ... provider, including SecondOpinions.com® – consumer division is gaining ... services. The telemedicine industry pioneer is now partnering ... Founded and established in 1963 as the first ... as a maternity care hospital with very few ...
Breaking Medicine News(10 mins):Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 2Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 3Health News:USARAD Holdings Inc. SECONDOPINIONS.COM® Partners With Prestigious Dar Al Shifa Hospital In Kuwait 4
... blockbuster drug and greater reimbursement levels for the treatment ... smoking cessation and addiction treatments are expected to ... 2005 to more than $2.3 billion in 2010, according ... Analysis, a new study released today from Kalorama Information. ...
... a computer based test that may reveal how easily an ... that her scientific test can be used as another ... in fields where employee distraction can lead to fatal errors. ... liable to do things like put your keys in the ...
... are hopeful that the actress' current rehab spell will bring ... wacky recent incidents . ,As the Mean Girls ... on May 28, after being arrested for DUI, her supposed ... ,One friend told America's Star magazine that Lohan ...
... of Illinois dentists provide oral cancer examinations for their ... thoroughly or at optimum intervals, according to a new ... of pre-malignant lesions and of proper examination techniques, some ... be doing to detect oral cancers in their patients," ...
... on Thursday announced that FDA has granted a standard ... Cervarix, Reuters reports. A GSK spokesperson on Thursday said ... been completed in six months. ,Cervarix and ... 100% effective in preventing infection with HPV strains 16 ...
... Dey, L.P. announced today that the U.S. Food ... Drug Application (NDA) of its marketing partner, Critical ... tablets. ZYFLO CR(TM) offers twice-daily, extended-release dosing. Under ... in March 2007, DEY will co-market Critical Therapeutics' ...
Cached Medicine News:Health News:Individuals Distraction can Be Measured by a Computer Based Test 2Health News:Dentists Need More Training in Oral Cancer Detection 2Health News:Dentists Need More Training in Oral Cancer Detection 3Health News:FDA Approves ZYFLO CR(TM) (Zileuton) for Chronic Treatment of Asthma 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: